Hims & Hers Health is trading 3.2% down today at €25.12 as the stock continues to digest volatility tied to recent FDA scrutiny of key peptide products.
- Shares are giving back recent gains following a mixed FDA Pharmacy Compounding Advisory Committee vote on seven peptides central to the company's offerings.
- Investors are currently reassessing regulatory and growth risks after a period of sharp selloffs and subsequent rebounds.